Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

por Kim, Bomin, Lee, Jungwook, Jang, Hyunwoo, Lee, Nami, Mehta, Jaydeep, Jang, Seong Bok
Publicado 2022

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

por Jang, Seong Bok, Kim, Kyeong Bae, Sim, Sujin, Cho, Byoung Chul, Ahn, Myung-Ju, Han, Ji-Youn, Kim, Sang-We, Lee, Ki Hyeong, Cho, Eun Kyung, Haddish-Berhane, Nahor, Mehta, Jaydeep, Oh, Se-Woong
Publicado 2021